Translational Development Acquisition (TDAC) Non-Current Deffered Revenue (2024 - 2026)

Translational Development Acquisition (TDAC) has 3 years of Non-Current Deffered Revenue data on file, last reported at $6.0 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $6.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $6.0 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $6.0 million in Q4 2024 to a low of $6.0 million in Q4 2024.
• A 3-year average of $6.0 million and a median of $6.0 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The widest YoY moves for Non-Current Deffered Revenue: up 0.0% in 2025, down 0.0% in 2025.
• Tracing TDAC's Non-Current Deffered Revenue over 3 years: stood at $6.0 million in 2024, then changed by 0.0% to $6.0 million in 2025, then changed by 0.0% to $6.0 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $6.0 million (Q1 2026), $6.0 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.